Clinical Trials · NCT00145405

Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction

Name: Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 4Octreotide Lanreotide

Phase: Phase 4
Recruitment status: Completed
Sponsor: Odense University Hospital
Enrollment: 12
Start date: Sep 2002
Locations: 1 site, Denmark
Primary endpoint: GH and IGF-I levels after 4, 6, 10, 12 months therapy.

View Octreotide compound reference